期刊
CANCER LETTERS
卷 499, 期 -, 页码 60-72出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.10.050
关键词
Molecular diagnostics; Surgery; Chemoradiation; Immune therapy; Target therapy
类别
资金
- National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme [81761168038]
- Beijing Municipal Administration of Hospitals' Mission Plan [SML20180501]
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2019-I2M5-021]
- National Natural Science Foundation of China [81672479, 81773208, 81702460, 81871013, 81802483, 81972337, 81902528, 81903060, 81903078, 81972816]
- National Key Research and Development Program of China [2018YFC0115604]
The joint guideline committee of Chinese Glioma Cooperative Group, Society for Neuro-Oncology of China, and Chinese Brain Cancer Association has updated the clinical practice guideline to provide recommendations for the diagnosis and management of diffuse gliomas. The guidelines focus on molecular and pathological diagnostics, as well as main treatment modalities including surgery, radiotherapy, and chemotherapy. Additionally, the guidelines integrate results from clinical trials of immune therapies and target therapies as future directions.
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据